Abstract
The use of general anaesthetics has facilitated great advantages in surgery within the last 150 years. General anaesthesia is composed of several components including analgesia, amnesia, hypnosis and immobility. To achieve these components, general anaesthetics have to act via multiple molecular targets at different anatomical sites in the central nervous system. Much of our current understanding of how anaesthetics work has been obtained within the last few years on the basis of genetic approaches, in particular knock-out or knock-in mice. Anaesthetic drugs can be grouped into volatile and intravenous anaesthetics according to their route of administration. Common volatile anaesthetics induce immobility via molecular targets in the spinal cord, including glycine receptors, GABAA receptors, glutamate receptors, and TREK-1 potassium channels. In contrast, intravenous anaesthetics cause immobility almost exclusively via GABAA receptors harbouring β3 subunits. Hypnosis is predominantly mediated by β3-subunit containing GABAA receptors in the brain, whereas β2 subunit containing receptors, which make up more than 50% of all GABAA receptors in the central nervous system, mediate sedation. At clinically relevant concentrations, ketamine and nitrous oxide block NMDA receptors. Unlike all other anaesthetics in clinical use they produce analgesia. Not only desired actions of anaesthetics, but also undesired side effects are linked to certain receptors. Respiratory depression involves β3 containing GABAA receptors whereas hypothermia is largely mediated by GABAA receptors containing β2 subunits. These recent insights into the clinically desired and undesired actions of anaesthetic agents provide new avenues for the design of drugs with an improved side-effect profile. Such agents would be especially beneficial for the treatment of newborn children, elderly patients and patients undergoing ambulatory surgery.
Keywords: Meyer-Overton correlation, Ligand gated ion channels, Synaptic Transmission, immobility, Sedation, NMDA receptors
Current Pharmaceutical Design
Title: Anaesthetic Drugs: Linking Molecular Actions to Clinical Effects
Volume: 12 Issue: 28
Author(s): Christian Grasshoff, Berthold Drexler, Uwe Rudolph and Bernd Antkowiak
Affiliation:
Keywords: Meyer-Overton correlation, Ligand gated ion channels, Synaptic Transmission, immobility, Sedation, NMDA receptors
Abstract: The use of general anaesthetics has facilitated great advantages in surgery within the last 150 years. General anaesthesia is composed of several components including analgesia, amnesia, hypnosis and immobility. To achieve these components, general anaesthetics have to act via multiple molecular targets at different anatomical sites in the central nervous system. Much of our current understanding of how anaesthetics work has been obtained within the last few years on the basis of genetic approaches, in particular knock-out or knock-in mice. Anaesthetic drugs can be grouped into volatile and intravenous anaesthetics according to their route of administration. Common volatile anaesthetics induce immobility via molecular targets in the spinal cord, including glycine receptors, GABAA receptors, glutamate receptors, and TREK-1 potassium channels. In contrast, intravenous anaesthetics cause immobility almost exclusively via GABAA receptors harbouring β3 subunits. Hypnosis is predominantly mediated by β3-subunit containing GABAA receptors in the brain, whereas β2 subunit containing receptors, which make up more than 50% of all GABAA receptors in the central nervous system, mediate sedation. At clinically relevant concentrations, ketamine and nitrous oxide block NMDA receptors. Unlike all other anaesthetics in clinical use they produce analgesia. Not only desired actions of anaesthetics, but also undesired side effects are linked to certain receptors. Respiratory depression involves β3 containing GABAA receptors whereas hypothermia is largely mediated by GABAA receptors containing β2 subunits. These recent insights into the clinically desired and undesired actions of anaesthetic agents provide new avenues for the design of drugs with an improved side-effect profile. Such agents would be especially beneficial for the treatment of newborn children, elderly patients and patients undergoing ambulatory surgery.
Export Options
About this article
Cite this article as:
Grasshoff Christian, Drexler Berthold, Rudolph Uwe and Antkowiak Bernd, Anaesthetic Drugs: Linking Molecular Actions to Clinical Effects, Current Pharmaceutical Design 2006; 12 (28) . https://dx.doi.org/10.2174/138161206778522038
DOI https://dx.doi.org/10.2174/138161206778522038 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Agents Complexing Copper as a Therapeutic Strategy for the Treatment of Alzheimers Disease
Current Alzheimer Research The 18-kDa Translocator Protein as a CNS Drug Target: Finding Our Way Through the Neuroinflammation Fog
CNS & Neurological Disorders - Drug Targets G Protein-Coupled Receptor Signaling Complexity in Neuronal Tissue:Implications for Novel Therapeutics
Current Alzheimer Research Intramolecular Immunological Signal Hypothesis Revived - Structural Background of Signalling Revealed by Using Congo Red as a Specific Tool
Mini-Reviews in Medicinal Chemistry Supervised Disulfiram as Adjunct to Psychotherapy in Alcoholism Treatment
Current Pharmaceutical Design Beneficial effect of minimal interference on item memory but not on source memory in Alzheimer's disease
Current Alzheimer Research Brain-derived Neurotrophic Factor Promotes Growth of Neurons and Neural Stem Cells Possibly by Triggering the Phosphoinositide 3-Kinase/ AKT/Glycogen Synthase Kinase-3β/β-catenin Pathway
CNS & Neurological Disorders - Drug Targets A Novel Relationship for Schizophrenia, Bipolar and Major Depressive Disorder Part 6: A Hint from Chromosome 6 High Density Association Screen
Current Molecular Medicine Update on the Cardiac Safety of Moxifloxacin
Current Drug Safety Modulation of Immunity and the Inflammatory Response: A New Target for Treating Drug-resistant Epilepsy
Current Neuropharmacology Aporphines and Parkinson’s Disease: Medical Tools for the Future
Current Topics in Medicinal Chemistry Activity of γ -Secretase on Substrates Other than APP
Current Topics in Medicinal Chemistry Brivaracetam Prevents the Over-expression of Synaptic Vesicle Protein 2A and Rescues the Deficits of Hippocampal Long-term Potentiation In Vivo in Chronic Temporal Lobe Epilepsy Rats
Current Neurovascular Research Olanzapine v Risperidone: A Contrast Between Atypical Antipsychotics Concerning Control of Schizophrenia
Current Psychopharmacology Treating Cancer in Older and Oldest Old Patients
Current Pharmaceutical Design In Silico Studies Most Employed in the Discovery of New Antimicrobial Agents
Current Medicinal Chemistry Endophenotypes and Biological Markers of Schizophrenia: From Biological Signs of Illness to Novel Treatment Targets
Current Pharmaceutical Design Flavonoids in Neurodegeneration: Limitations and Strategies to Cross CNS Barriers
Current Medicinal Chemistry Age-Related Changes in P-Glycoprotein Expression in Senescence- Accelerated Mouse
Current Aging Science Dispensing Patterns of Anxiolytics and Sedative-Hypnotics: A Feasibility Study Comparing Datasets from a Developed and a Developing Country (Australia and South Africa)
Current Drug Safety